SPS
GPCR icon

Susquehanna Portfolio Strategies’s Structure Therapeutics GPCR Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio GPCR Stock Details GPCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.99M Buy
148,948
+88,431
+146% +$3.91M 0.13% 212
2026
Q1 		$2.92M Sell
60,517
-7,572
-11% -$518K 0.04% 406
2025
Q4 		$4.74M Buy
68,089
+12,147
+22% +$496K 0.07% 313
2025
Q3 		$1.57M Buy
55,942
+15,982
+40% +$318K 0.02% 566
2025
Q2 		$829K Buy
+39,960
New +$879K 0.02% 548

Other funds holding GPCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Susquehanna Portfolio Strategies's GPCR Position: Q2 2026 in Review

Susquehanna Portfolio Strategies increased its Structure Therapeutics (GPCR) stake by 146% in Q2 2026, buying an estimated $3.91M and bringing the position to 148,948 shares worth $7.99M. The position accounts for 0.13% of the portfolio, ranked #212.

Susquehanna Portfolio Strategies first reported a position in GPCR in Q2 2025 and has held it in 5 quarters since. 191 funds tracked by Wall St. Rank hold GPCR as of Q2 2026.

  • Susquehanna Portfolio Strategies held 148,948 shares of Structure Therapeutics worth $7.99M as of Q2 2026.
  • Susquehanna Portfolio Strategies bought 88,431 Structure Therapeutics shares in Q2 2026, an estimated $3.91M.
  • Structure Therapeutics made up 0.13% of Susquehanna Portfolio Strategies's portfolio in Q2 2026, its #212 holding.
  • Susquehanna Portfolio Strategies first reported a position in Structure Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 191 funds tracked by Wall St. Rank held Structure Therapeutics as of Q2 2026.

Based on Susquehanna Portfolio Strategies's 13F filing for Q2 2026, filed 14 Aug 2026.